Form 4: BioCardia CEO Peter Altman Increases Stake in Company

BioCardia's CEO, Peter Altman, recently purchased additional shares of the company's common stock, increasing his beneficial ownership.

Summary

• On April 2, 2025, Peter Altman, the President and CEO of BioCardia, Inc., acquired 500 shares of common stock at a weighted average price of $2.23 per share, in multiple trades ranging from $2.16 to $2.28.
• Following this transaction, Altman directly owns 110,120 shares of BioCardia common stock.
• On April 3, 2025, Altman acquired an additional 600 shares of common stock at a weighted average price of $2.20 per share, in multiple trades ranging from $2.15 to $2.29.
• Following this transaction, Altman directly owns 110,720 shares of BioCardia common stock.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive due to the CEO's increased investment in the company, which can be seen as a vote of confidence. However, it's a relatively small transaction.

Positives

• The CEO's purchase of additional shares could be interpreted as a sign of confidence in the company's future prospects.

Industry Context

Insider buying is often seen as a positive signal, suggesting that a company's leadership believes the stock is undervalued.

Stakeholder Impact

• Shareholders may view the CEO's purchase as a positive signal.

Key Dates

Keywords

BioCardia, Peter Altman, Insider Trading, Share Purchase, Common Stock, BCDA